Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies.
about
High frequency of CD4+ CXCR5+ TFH cells in patients with immune-active chronic hepatitis BThe expression of TLR-9, CD86, and CD95 phenotypes in circulating B cells of patients with chronic viral hepatitis B or C before and after antiviral therapy.Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients.Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencingAntiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients.Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.Characterization of the liver-draining lymph nodes in mice and their role in mounting regional immunity to HBVRelationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir.Antiviral treatment improves disrupted peripheral B lymphocyte homeostasis in chronic hepatitis B virus-infected patients.Polymorphism of estrogen receptor alpha (ESR1) is associated with virological response to entecavir (ETV) in nucleoside-naïve adult patients with chronic hepatitis B.Decreased CD27 on B lymphocytes in patients with primary hepatocellular carcinoma.
P2860
Q33959352-AAD415D3-3A9C-4980-A834-7415C1F11886Q35372981-B6A07055-53F0-4E89-BD4D-433F5F4EB670Q36153775-639040CC-5B5F-46A5-A5C9-A3A1C8A1B322Q36395364-82F81A2D-EE13-4F8F-B253-A4B781C77A48Q36487681-D5261F68-AEAD-48EC-B851-B8E00E7D8F60Q36667147-47B3B268-A651-4E43-A296-E3964EF629B1Q37165176-4365695B-8AD4-48DD-B46F-C437240A69ABQ37729356-07E07730-1363-4E59-9A1A-9544D0D3E4AEQ38738345-804F8D11-0804-4111-BCB4-10A1C46F7C77Q42221830-7AECC9BA-8844-4609-88BA-65AB536D4FCFQ42265392-50E8D426-D300-4545-8E52-CF60EA127A6EQ42288459-F171D6AA-DDC3-4C56-B33C-29A294B92A3BQ50961515-38232161-B8C5-4F32-889E-D071AD3809EF
P2860
Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enhancing the antihepatitis B ...... voxil and entecavir therapies.
@en
Enhancing the antihepatitis B ...... voxil and entecavir therapies.
@nl
type
label
Enhancing the antihepatitis B ...... voxil and entecavir therapies.
@en
Enhancing the antihepatitis B ...... voxil and entecavir therapies.
@nl
prefLabel
Enhancing the antihepatitis B ...... voxil and entecavir therapies.
@en
Enhancing the antihepatitis B ...... voxil and entecavir therapies.
@nl
P2093
P2860
P356
P1476
Enhancing the antihepatitis B ...... voxil and entecavir therapies.
@en
P2093
Guijie Xin
Hong Zhang
Hongqing Yan
Jingjing Liu
Pinghui Sun
Yanfang Jiang
P2860
P2888
P356
10.1038/CMI.2010.37
P577
2010-10-04T00:00:00Z